Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2012 | Original Article

Longitudinal imaging of Alzheimer pathology using [¹¹C]PIB, [¹⁸F]FDDNP and [¹⁸F]FDG PET

Authors: Rik Ossenkoppele, Nelleke Tolboom, Jessica C. Foster-Dingley, Sofie F. Adriaanse, Ronald Boellaard, Maqsood Yaqub, Albert D. Windhorst, Frederik Barkhof, Adriaan A. Lammertsma, Philip Scheltens, Wiesje M. van der Flier, Bart N. M. van Berckel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2012

Abstract

Purpose

[¹¹C]PIB and [¹⁸F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [¹⁸F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients with AD or mild cognitive impairment (MCI) and in healthy controls.

Methods

Longitudinal, paired, dynamic [¹¹C]PIB and [¹⁸F]FDDNP (90 min each) and static [¹⁸F]FDG (15 min) PET scans were obtained in 11 controls, 12 MCI patients and 8 AD patients. The mean interval between baseline and follow-up was 2.5 years (range 2.0–4.0 years). Parametric [¹¹C]PIB and [¹⁸F]FDDNP images of binding potential (BP_ND) and [¹⁸F]FDG standardized uptake value ratio (SUVr) images were generated.

Results

A significant increase in global cortical [¹¹C]PIB BP_ND was found in MCI patients, but no changes were observed in AD patients or controls. Subsequent regional analysis revealed that this increase in [¹¹C]PIB BP_ND in MCI patients was most prominent in the lateral temporal lobe (p < 0.05). For [¹⁸F]FDDNP, no changes in global BP_ND were found. [¹⁸F]FDG uptake was reduced at follow-up in the AD group only, especially in frontal, parietal and lateral temporal lobes (all p < 0.01). Changes in global [¹¹C]PIB binding (ρ = −0.42, p < 0.05) and posterior cingulate [¹⁸F]FDG uptake (ρ = 0.54, p < 0.01) were correlated with changes in Mini-Mental-State Examination score over time across groups, whilst changes in [¹⁸F]FDDNP binding (ρ = −0.18, p = 0.35) were not.

Conclusion

[¹¹C]PIB and [¹⁸F]FDG track molecular changes in different stages of AD. We found increased amyloid load in MCI patients and progressive metabolic impairment in AD patients. [¹⁸F]FDDNP seems to be less useful for examining disease progression.

Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56–67.PubMedCrossRef

Stam CJ, de Haan W, Daffertshofer A, Jones BF, Manshanden I, van Cappellen van Walsum AM, et al. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain. 2009;132:213–24.PubMedCrossRef

Silverman DHS, Small GW, Chang CY, Lu CS, de Aburto MAK, Chen W, et al. Positron emission tomography in evaluation of dementia. JAMA. 2001;286:2120–7.PubMedCrossRef

Klunk WE, Engler H, Nordberg A, Wang Y, Blomquist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRef

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and Tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63.PubMedCrossRef

Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009;50:191–7.PubMedCrossRef

Tolboom N, Flier WM, Boverhoff J, Yaqub M, Wattjes M, Raijmakers PG, et al. Molecular imaging in the diagnosis of Alzheimer's disease: visual interpretation of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry. 2010;81:882–4.PubMedCrossRef

Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48:547–52.PubMedCrossRef

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456–65.PubMedCrossRef

10.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73:754–60.PubMedCrossRef

11.

Villemagne VL, Pike K, Chetelat G, Ellis KA, Mulligan R, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.PubMedCrossRef

12.

Koivunen J, Scheinin M, Virta JR, Aalto S, Vahlberg T, Nagren K, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76:1085–90.PubMedCrossRef

13.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856–66.PubMedCrossRef

14.

Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012;33:198.e1–14.CrossRef

15.

Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73:1186–92.PubMedCrossRef

16.

Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. The Alzheimer's disease neuroimaging initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355–65.PubMedCrossRef

17.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.PubMedCrossRef

18.

Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage. 2008;43:236–44.PubMedCrossRef

19.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21:RC189.PubMed

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–44.PubMed

21.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef

22.

Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med. 1997;38:1614–23.PubMed

23.

Wilson AA, Garcia A, Chestaskova A, Kung HF, Houle SA. A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-(′4-methylaminophenyl)-6-hydroxybenzothiazole ([C-11]-6-OH-BTA-1). J Labelled Comp Radiopharm. 2004;47:679–82.CrossRef

24.

Klok RP, Klein PJ, van Berckel BNM, Tolboom N, Lammertsma AA, Windhorst AD. Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). Appl Radiat Isot. 2008;66:203–7.PubMedCrossRef

25.

Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969–79.PubMedCrossRef

26.

Wu Y, Carson R. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440–52.PubMedCrossRef

27.

Yaqub M, Tolboom N, Boellaard R, van Berckel BNM, van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage. 2008;42:76–86.PubMedCrossRef

28.

Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage. 2010;49:433–41.PubMedCrossRef

29.

Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. 1989;77:314–9.PubMedCrossRef

30.

Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–28.PubMedCrossRef

31.

Hardy JA, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;197:353–6.CrossRef

32.

Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993;52:594–600.PubMedCrossRef

33.

Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, et al. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci. 2001;21:858–64.PubMed

34.

Bouwman FH, van der Flier WM, Schoonenboom NSM, van Elk EJ, Kok A, Rijmen F, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology. 2007;69:1006–11.PubMedCrossRef

35.

Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem. 2009;109:623–30.PubMedCrossRef

36.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50:1464–70.PubMedCrossRef

37.

Tolboom N, Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology. 2009;73:2079–85.PubMedCrossRef

38.

Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738–45.PubMedCrossRef

39.

Forster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2011. doi:10.1016/j.biopsych.2011.04.023

40.

van der Vlies AE, Koedam ELGE, Pijnenburg YAL, Twisk JWR, Scheltens P, van der Flier WM. Most rapid cognitive decline in APOE E4 negative Alzheimer's disease with early onset. Psychol Med. 2009;39:1907–11.PubMedCrossRef

41.

Verhage F. Intelligentie en leeftijd: onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar [Intelligence and age: study with Dutch people aged 12 to 77]. Assen: Van Gorcum; 1964.

Title: Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Authors: Rik Ossenkoppele
Nelleke Tolboom
Jessica C. Foster-Dingley
Sofie F. Adriaanse
Ronald Boellaard
Maqsood Yaqub
Albert D. Windhorst
Frederik Barkhof
Adriaan A. Lammertsma
Philip Scheltens
Wiesje M. van der Flier
Bart N. M. van Berckel
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2102-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Longitudinal imaging of Alzheimer pathology using [¹¹C]PIB, [¹⁸F]FDDNP and [¹⁸F]FDG PET

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2012

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

Quantification of myocardial blood flow with 82Rb positron emission tomography: clinical validation with 15O-water

MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer

Comment on Reyes et al.: Myocardial perfusion scintigraphy in Europe 2007: a survey of the European Council of Nuclear Cardiology